Evaluating the combined effect of a choline kinase inhibitor and temozolomide therapy in a mouse model of glioblastoma using 1 H MR spectroscopy and IVIM-DWI

This study evaluated the therapeutic efficacy of combining a choline kinase alpha (ChoKα) inhibitor, MN58b, and Temozolomide (TMZ) in a syngeneic GL261 glioblastoma (GBM) mouse model. It used MR spectroscopy (MRS) and intravoxel incoherent motion diffusion-weighted imaging (IVIM-DWI) to assess metabolic and microstructural changes within the tumour.